Evidence-Based Medicine Guidelines
Nafarelin in the treatment of leiomyomas
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Nafarelin in the Treatment of Leiomyomas." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/456916/all/Nafarelin_in_the_treatment_of_leiomyomas.
Nafarelin in the treatment of leiomyomas. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. https://evidence.unboundmedicine.com/evidence/view/EBMG/456916/all/Nafarelin_in_the_treatment_of_leiomyomas. Accessed December 2, 2024.
Nafarelin in the treatment of leiomyomas. (2024). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/456916/all/Nafarelin_in_the_treatment_of_leiomyomas
Nafarelin in the Treatment of Leiomyomas [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. [cited 2024 December 02]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/456916/all/Nafarelin_in_the_treatment_of_leiomyomas.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Nafarelin in the treatment of leiomyomas
ID - 456916
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/456916/all/Nafarelin_in_the_treatment_of_leiomyomas
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
